Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HYH2006078P1
- Development stage
- Phase 1
- Lead developer
- Tiandi Hengyi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
HYH2006078P1 is an investigational small molecule sedative and anesthetic agent developed by Tiandi Hengyi Pharmaceutical. It is currently in Phase 1 clinical development for procedural sedation and anesthesia in patients undergoing non-intubated procedures. Administered intravenously, the drug is designed to provide rapid-acting sedation with a predictable recovery profile, potentially offering an alternative to standard agents like propofol or midazolam in the clinical setting of minor surgeries and diagnostic interventions. The development program includes dose-escalation studies in healthy volunteers to evaluate safety, tolerability, pharmacokinetics, and exploratory pharmacodynamics.
02
Targets
GABRR (GABA-A receptor subunit rho)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on HYH2006078P1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HYH2006078P1.